OncLive TV

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on the escalating costs associated with cancer car

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, talks about her presentation at 2011 ASCO Genitourinary conference.

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Talks About Her Involvement in New Clinical Trials

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses Recent Pazopanib Clinical Trials.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.